Foam in wound treatment

US11224676B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11224676-B2
Application numberUS-201816607435-A
CountryUS
Kind codeB2
Filing dateJun 5, 2018
Priority dateJun 9, 2017
Publication dateJan 18, 2022
Grant dateJan 18, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a hydrophilic foam material, which is of particular use in wound treatment, and to a method for producing said hydrophilic foam material. The hydrophilic foam material has nucleating particles, wherein at least 85% of all foam cells in said foam material have an average cell size of 0.01 mm2 or less.

First claim

Opening claim text (preview).

The invention claimed is: 1. A hydrophilic polyurethane foam material comprising alumina trihydrate nucleating particles, which are present at a concentration of from 5% to 25% by weight of said foam material, relative to the overall weight of the foam material, wherein at least 85% of all foam cells in said foam material have an average cross-sectional cell size of 0.01 mm2 or less, as measured by image analysis based on ISO 13322-1:2014, wherein said foam material has a free swell absorptive capacity, as measured according to EN 13726-1:2002, of at least 800 kg/m 3 . 2. The hydrophilic polyurethane foam material according to claim 1 , wherein said nucleating particles have a median particle size distribution in the range of from 1 to 30 μm. 3. The hydrophilic polyurethane foam material according to claim 1 , wherein at least 99% said nucleating particles are encapsulated within said foam material. 4. The hydrophilic polyurethane foam material according to claim 1 , wherein said foam material further comprises a surfactant present at a concentration of from 0.05 to 0.5% by weight, relative to the overall weight of the foam material. 5. The hydrophilic polyurethane foam material according to claim 1 , wherein said foam material has a speed of absorption of at least 5 μL/sec, as measured according to TAPPI standard T558 OM-97, using 30 μL Solution A, according to EN 13726-1:2002, as test solution. 6. The hydrophilic polyurethane foam material according to claim 1 , wherein said hydrophilic polyurethane foam material is partially obtained from a prepolymer comprising or being an isocyanate-capped polyol or isocyanate-capped polyurethane. 7. The hydrophilic polyurethane foam material according to claim 6 , wherein said polyol is selected from the group consisting of a polyester polyol, polyacrylate polyol, polyurethane polyol, polycarbonate polyol, polyether polyol, polyester-polyacrylate polyol, polyurethane polyacrylate polyol, polyurethane polyester polyol, polyurethane polyether polyol, polyurethane polycarbonate polyol, and polyester polycarbonate polyol. 8. The hydrophilic polyurethane foam material according to claim 6 , wherein said prepolymer derives from a reaction between a polyol, and a diisocyanate compound selected from the group consisting of hexamethylene diisocyanate (HDI), toluene diisocyanate (TDI), methylene diphenyl diisocyanate (MDI), isophorone diisocyanate (IPDI), and any mixture thereof. 9. A medical dressing comprising a layer of the hydrophilic polyurethane foam material according to claim 1 . 10. The medical dressing according to claim 9 , wherein said medical dressing further comprises at least one further layer. 11. A method for producing the hydrophilic polyurethane foam material accordingly to claim 1 , comprising the steps of: (i) preparing an aqueous mixture, (ii) mixing said aqueous mixture with a prepolymer composition, and (iii) allowing the resulting emulsion to cure wherein alumina trihydrate nucleating particles, at a concentration of from 5% to 25% by weight of said prepolymer composition, are added to said aqueous mixture in step (i) and/or are present in said prepolymer composition of step (ii).

Assignees

Inventors

Classifications

  • containing foams · CPC title

  • by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum · CPC title

  • Surfactants · CPC title

  • Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step · CPC title

  • Micropores, i.e. average diameter being between 0,1 micrometer and 0,1 millimeter · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11224676B2 cover?
The present invention relates to a hydrophilic foam material, which is of particular use in wound treatment, and to a method for producing said hydrophilic foam material. The hydrophilic foam material has nucleating particles, wherein at least 85% of all foam cells in said foam material have an average cell size of 0.01 mm2 or less.
Who is the assignee on this patent?
Moelnlycke Health Care Ab
What technology area does this patent fall under?
Primary CPC classification A61L15/26. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).